Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating) – Jefferies Financial Group decreased their Q1 2022 earnings estimates for shares of Alnylam Pharmaceuticals in a research note issued to investors on Monday, April 25th. Jefferies Financial Group analyst M. Raycroft now forecasts that the biopharmaceutical company will post earnings of ($1.86) per share for the quarter, down from their prior forecast of ($1.80). Jefferies Financial Group also issued estimates for Alnylam Pharmaceuticals’ FY2022 earnings at ($6.53) EPS and FY2024 earnings at ($2.36) EPS.
ALNY has been the topic of several other reports. Piper Sandler raised Alnylam Pharmaceuticals from a “neutral” rating to an “overweight” rating and increased their target price for the stock from $181.00 to $208.00 in a research report on Monday, January 3rd. SVB Leerink cut their target price on Alnylam Pharmaceuticals from $109.00 to $103.00 and set a “market perform” rating on the stock in a research report on Friday, February 11th. Morgan Stanley lowered Alnylam Pharmaceuticals from an “overweight” rating to an “equal weight” rating and cut their target price for the stock from $210.00 to $178.00 in a research report on Monday. Citigroup assumed coverage on Alnylam Pharmaceuticals in a research report on Monday, February 28th. They issued a “buy” rating and a $223.00 target price on the stock. Finally, Bank of America reiterated a “buy” rating and issued a $211.00 price target on shares of Alnylam Pharmaceuticals in a report on Monday, January 3rd. Four analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $218.71.
Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Rating) last issued its quarterly earnings results on Thursday, February 10th. The biopharmaceutical company reported ($2.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.47) by ($0.69). The business had revenue of $258.10 million for the quarter, compared to analysts’ expectations of $233.62 million. Alnylam Pharmaceuticals had a negative return on equity of 109.21% and a negative net margin of 101.01%. The company’s revenue for the quarter was up 57.8% compared to the same quarter last year. During the same period in the prior year, the company earned ($2.09) EPS.
A number of large investors have recently bought and sold shares of ALNY. Norges Bank acquired a new position in Alnylam Pharmaceuticals in the fourth quarter worth about $215,229,000. Lord Abbett & CO. LLC bought a new position in Alnylam Pharmaceuticals in the third quarter worth about $52,867,000. BlackRock Inc. lifted its holdings in Alnylam Pharmaceuticals by 2.6% in the third quarter. BlackRock Inc. now owns 8,920,972 shares of the biopharmaceutical company’s stock worth $1,684,369,000 after acquiring an additional 224,569 shares during the last quarter. Baillie Gifford & Co. lifted its holdings in Alnylam Pharmaceuticals by 1.9% in the fourth quarter. Baillie Gifford & Co. now owns 10,616,751 shares of the biopharmaceutical company’s stock worth $1,800,388,000 after acquiring an additional 200,967 shares during the last quarter. Finally, Polar Capital Holdings Plc lifted its holdings in Alnylam Pharmaceuticals by 59.5% in the third quarter. Polar Capital Holdings Plc now owns 523,712 shares of the biopharmaceutical company’s stock worth $98,882,000 after acquiring an additional 195,430 shares during the last quarter. Institutional investors and hedge funds own 90.64% of the company’s stock.
In related news, Director Steven M. Paul sold 15,000 shares of Alnylam Pharmaceuticals stock in a transaction dated Friday, April 1st. The stock was sold at an average price of $170.69, for a total value of $2,560,350.00. Following the completion of the transaction, the director now directly owns 1,000 shares in the company, valued at $170,690. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 2.30% of the stock is currently owned by company insiders.
Alnylam Pharmaceuticals Company Profile (Get Rating)
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases.
- Get a free copy of the StockNews.com research report on Alnylam Pharmaceuticals (ALNY)
- Las Vegas Sands Stock Could be a Winning Bet Down Here
- Newmont Corporation is the Same as It’s Always Been Which is Why It’s a Buy
- Simpson Manufacturing Co. Hits The Nail On The Head, Again
- The Sherwin-Williams Company Bottoms Above Institutional Support
- What To Make Of Activision Blizzard (NASDAQ: ATVI)
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.